ZA200704464B - Device and method for identifying and treating vaginal affections - Google Patents
Device and method for identifying and treating vaginal affections Download PDFInfo
- Publication number
- ZA200704464B ZA200704464B ZA200704464A ZA200704464A ZA200704464B ZA 200704464 B ZA200704464 B ZA 200704464B ZA 200704464 A ZA200704464 A ZA 200704464A ZA 200704464 A ZA200704464 A ZA 200704464A ZA 200704464 B ZA200704464 B ZA 200704464B
- Authority
- ZA
- South Africa
- Prior art keywords
- lactobacillus
- vaginal
- glove
- lactic acid
- affection
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 94
- 239000000203 mixture Substances 0.000 claims description 70
- 241000894006 Bacteria Species 0.000 claims description 68
- 239000004310 lactic acid Substances 0.000 claims description 47
- 235000014655 lactic acid Nutrition 0.000 claims description 47
- 206010046914 Vaginal infection Diseases 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 41
- 241000186660 Lactobacillus Species 0.000 claims description 35
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 29
- 201000008100 Vaginitis Diseases 0.000 claims description 29
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 28
- 240000001929 Lactobacillus brevis Species 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 26
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 25
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 24
- 239000000306 component Substances 0.000 claims description 24
- 239000010410 layer Substances 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 22
- 241000186000 Bifidobacterium Species 0.000 claims description 21
- 210000003811 finger Anatomy 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 241000894007 species Species 0.000 claims description 14
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 13
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 13
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 239000000003 vaginal tablet Substances 0.000 claims description 10
- 241000193815 Atopobium minutum Species 0.000 claims description 9
- 241001430190 Eggerthia catenaformis Species 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 244000199866 Lactobacillus casei Species 0.000 claims description 7
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 7
- 241001561398 Lactobacillus jensenii Species 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 229940017800 lactobacillus casei Drugs 0.000 claims description 7
- -1 non-woven Substances 0.000 claims description 7
- 229940111630 tea tree oil Drugs 0.000 claims description 7
- 239000010677 tea tree oil Substances 0.000 claims description 7
- 206010017533 Fungal infection Diseases 0.000 claims description 6
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 210000003813 thumb Anatomy 0.000 claims description 6
- 229940044977 vaginal tablet Drugs 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 208000004483 Dyspareunia Diseases 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 5
- 210000003097 mucus Anatomy 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 229960000282 metronidazole Drugs 0.000 claims description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 241000604451 Acidaminococcus Species 0.000 claims description 3
- 241000157921 Actinotalea fermentans Species 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 3
- 241000186014 Bifidobacterium angulatum Species 0.000 claims description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 241000186011 Bifidobacterium catenulatum Species 0.000 claims description 3
- 241000186020 Bifidobacterium dentium Species 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 3
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims description 3
- 241001134659 Lactobacillus curvatus Species 0.000 claims description 3
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 3
- 241001134654 Lactobacillus leichmannii Species 0.000 claims description 3
- 241001438705 Lactobacillus rogosae Species 0.000 claims description 3
- 241000194037 Lactococcus raffinolactis Species 0.000 claims description 3
- 241001134720 Rhodoferax fermentans Species 0.000 claims description 3
- 241000605082 Saccharicrinis fermentans Species 0.000 claims description 3
- 244000057717 Streptococcus lactis Species 0.000 claims description 3
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 3
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 3
- 241000588902 Zymomonas mobilis Species 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 241000186679 Lactobacillus buchneri Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 claims description 2
- 229940012189 methyl orange Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 229940000425 combination drug Drugs 0.000 claims 7
- 241000186148 Bifidobacterium pseudolongum Species 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000010495 camellia oil Substances 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 description 22
- 239000000523 sample Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000003756 cervix mucus Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010046901 vaginal discharge Diseases 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007793 ph indicator Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000005107 Premature Birth Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000013464 vaginal disease Diseases 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010060937 Amniotic cavity infection Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000008158 Chorioamnionitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- 241000203736 Mobiluncus Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 241000203475 Neopanax arboreus Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010036603 Premature rupture of membranes Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000019812 amnionitis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001496 desquamative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Description
Device and method for identifying and treating vaginal affections
The present invention relates to a device and a method using said de- : vice for the diagnosis of vaginal affections, such as infections, in par- ticular bacterial vaginosis, or vaginitis, in women by using an identifi- able indicator. In particular, the present invention relates to a pH test glove bearing a reporter substance indicating the possible presence of vaginal affection.
The present invention relates to improving the health of women hav- ing vaginal affections and to procedures for determining the presence of a vaginal affection and, if present, topical use of a gynecological composition, preferably comprising Lactobacillus strains and/or Bifi- dobacteria. In a preferred aspect, the invention relates to a method for determining the presence of a vaginal affection in a subject using an identifiable indicator and, if the indication is positive, the use of a gy- necological composition comprising one or more Lactobacillus strains and/or Bifidobacteria administered locally in an amount effective to treat the vaginal affection. Also described are packages or kits includ- ing a probe or tool such as a glove bearing a reporter substance indi- cating the presence of an affection packaged together with a gyneco- logical composition for treating the vaginal affections, if it is found to be present.
The expression vaginal affections as used herein includes vaginal in- fections, such as bacterial vaginosis, fungal and viral infection, and vaginitis. Presence of a vaginal affection may be indicated by change in the pH of vaginal fluid, vaginal discharge, possible presence of indica- tor cells or strong or bad odor, vaginal discomfort, such as itching and burning. The gynecological compositions of the invention are also bene- ficial in the prevention or treatment of dyspareunia of which a vaginal infection is one of the causes.
Vaginitis is an inflammation of the lining of the vagina, which can be the result of a physical, chemical or biological agent. The present in- vention applies to every form of vaginitis.
Bacterial vaginosis (BV) is the most common vaginal disorder among reproductive age women, with prevalence from 10% to 40% in the en- tire female population, and from 5% to 50% among pregnant women.
BV is not caused by one specific pathogenic microorganism, but rather, by an imbalance of vaginal microbial flora.
Lactobacilli, that represent the prevalent microorganisms of the healthy human vagina, are reduced or absent in BV, particularly the
H203-producing strains, and are replaced by Gardnerella vaginalis and other anaerobic microorganisms, such as Bacteroides spp., Mobiluncus spp., Prevotella spp., Peptostreptococcus spp. Ureaplasma urealyticum, and Mycoplasma hominis, most of which are normally found in the . healthy vagina in small amounts.
Women with vaginal affection, in particular BV typically complain of vaginal discomfort and clinical symptoms, such as homogeneous malo- dorous vaginal discharge, more noticeable after unprotected inter- course, although some women are asymptomatic.
Often previously ignored or underestimated, the importance of vaginal flora in maintaining other aspects of health is now becoming increas- ingly understood.
Significant alterations in the vaginal microflora, such as those occur- ring in BV, have been associated with ascending infection, including pelvic inflammatory disease and obstetric complications such as pre- mature rupture of membranes, amnionitis, post-partum endometritis, late miscarriage, and elevated risk of preterm birth.
Increasing data also suggest that abnormal vaginal flora may be a risk factor for recurrent urinary tract infection and the complications aris- ing from BV include increased risk of sexually transmitted diseases, including human immunodeficiency virus.
Lactobacilli, particularly the H202 producing ones, play a pivotal role in controlling the microenvironment of the vagina and inhibiting the overgrowth of potentially pathogenic organisms. Possible mechanisms of this protection include inactivation of pathogens by different meta- bolic lactobacilli by-products (lactic acid, H20s, bacteriocins), competi- tion for epithelial cell attachment sites and stimulation of the local immune system. HzOz-producing strains of lactobacilli have been found in 70-96% of healthy women with normal flora, yet only 5% of women with BV.
BV infection is characterized by the presence of three of five criteria: release of an amine fishy odour, release of amine odour after addition of 10% potassium hydroxide solution, vaginal pH higher than 4.5, while the normal pH is between 3.8 and 4.5, presence of clue cells in the vaginal fluid, and milky homogenous vaginal discharge.
In most cases, the vaginal pH provides an early indication of any ab- normality in the vaginal environment that often encourage the devel- opment of infections.
The increasing colonisation of the vagina by infectious bacteria often goes unnoticed by the mother-to-be. If an infection of this kind is de- tected early, prompt medical treatment can be given and the risk of premature birth reduced.
That is why it is so important to start measuring the pH of the vagina regularly from as early as possible in the pregnancy and to ascertain it is comprised between 3.8 and 4.5.
Different products to the purpose are available on the market.
Such products including disposable gynecological examination gloves, bearing thereon a pH-sensitive test indicator, such as CarePlan® VpH gynecological examination gloves marketed by Selfcare Inc, are com- mercially available. Alternatively FemExam®, a combined pH and amine test card is available from CooperSurgical, Inc.
The CarePlan® VpH test is designed for measuring the acidity of the vaginal environment. This glove is coated with a pH indicator on the index finger and there is a colour scale on the back of the pack to read the test result. The problem with this product is that the index finger, coated with a pH indicator, is inserted in the vagina and in this way chemical substances could enter the vagina and cause inflammation and/or toxic damages. Moreover, excess mucus and/or discharges often present in the vagina remain on the glove finger and this excess could change the pH tester results.
The CarePlan® VpH test is made of polyethylene, a low quality mate- rial, which is not adherent to the different size of different user's hand, therefore unsuitable for an accurate sampling in the vagina.
The FemExam® is a credit-card size device having colorimetric test cir- cular areas to distinguish pH 4.7 or greater as well as for the presence of volatile amines, both indicators of a bacterial vaginal infection.
In the use of this device, a cotton-tipped swab or similar arrangement is used to collect and apply a sample of vaginal fluid to the test areas.
If present, elevated vaginal pH is noted and in a separate test area the presence of volatile amines is also reported.
The use of different components in the device, the swab and the card with test areas, can make the use of the device difficult. In addition, the swab could be of damage to the external orifice of the urethra or unwillingly left in the vagina.
Moreover the FemExam® only distinguishes pH 4.7 or greater, whereas pH 4.5 is already a sign of the presence of BV, therefore a sign of infection can be lost by the subject making self-examination.
It is important to know that pH 4.6 is a landmark to distinguish a physiological condition from a pathological one.
Therefore, there is still the need of a device for self-examination for de- tecting a vaginal affection, which is easy to use, safe, accurate and ca- pable of detecting early signs of the presence of an affection.
The present invention provides an easy, risk-free, painless way to measure the vaginal pH, one of the most important signs to check for any abnormality in the vagina and for the presence and development of vaginal affection, such as vaginal infection and vaginitis, in par- ticular bacterial vaginosis infections.
The present invention provides a glove bearing a reporter substance indicating the presence of a vaginal affection, said glove being charac- terized in that first means for detecting pH and second means for col- lecting a vaginal sample are provided thereon.
By the construction of the glove according to the present invention, the self-examination can be done in an easy, relaxed way and, most impor- tant, no chemicals, such as those present on the pH detecting means according to the construction of gloves of the prior art, are introduced in the vagina. Moreover, the pH detecting means is not altered by the possible presence of excess mucus and/or discharges, which are often present in the vagina. There is no risk to harm vagina and no foreign material can be left into it.
According to the present invention, the glove is provided with first . means for detecting pH and second means for collecting a vaginal sample, said means are arranged in a separate way on the glove in such a way the collecting means can be used without interfering with the means for detecting pH and said collecting means, having the vaginal sample thereon, can be subsequently contacted with said means for detecting pH.
According to the present invention, the term "provided" is used with the meaning that the first and second means are placed on the glove and "placed" means either "attached on" or “inserted in" or "coated on" or "embedded into".
In one embodiment of the present invention, said second means are placed or coated on one finger of the glove, preferably index or medium finger and said first means are placed on any position of the glove which can be contacted by the finger bearing said second means. For example, said first means can be placed on the thumb finger or on the surface of the glove in such a way the finger bearing said second means can be put into contact with said first means, for example on the palm or any other opposable finger.
Any other arrangement can be put into practice so as to allow said first and second means to be put into contact after vaginal sampling.
A preferred embodiment provides said first means placed on the thumb finger and said second means placed on the index or medium finger.
Any of the normally available pH-detecting means placed on the thumb finger can be used in the glove of the present invention, such as a normal litmus paper.
pH detection means can cover the full pH range. Conveniently, pH de- tection means are set to cover pH range from 3.8 to 4.5.
More conveniently, said pH detection means are set to detect values above pH 4.5.
A preferred embodiment of the present invention provides a mixture of pH indicator consisting of Methylorange and Bromocresol Green in the 1:5 (w/w) ratio. The color change range is between pH 3.8 and 4.5.
Any piece of information about pH reading can accompany the glove of the present invention, such as a colour scale. The piece of information can also contain warnings about pH range or value above which a medical advice is suggested. A pH value of 4.5 or higher is a warning for the affection, in particular BV.
The means for collecting vaginal sample, on an opposable finger, are made of a material suitable for collecting vaginal fluid and/or mucus.
In a preferred embodiment of the present invention the material is an absorbent, non-woven, mono layer gauze.
In one of the possible embodiments of the present invention, the means for collecting vaginal sample are placed on the index finger.
In another possible embodiment of the present invention, the glove can be shaped in any different way than the five-finger glove. It is impor- tant that the glove bears pH detecting means and vaginal sample col- lecting means separately, i.e. in a way such that the collecting means and the detecting means do not come into contact during the sampling operation, but can be put into contact subsequently. For example a two-finger shaped glove, a thumb and a single part for all the remain- ing fingers, is a convenient embodiment.
Since the means for collecting vaginal sample and the means for de- tecting pH are separated, the former can be drained from excess of sample, thus providing more accurate pH detection.
n “
The glove is made of any compatible material. A suitable material is low-density polyethylene (LDPE), but vinyl or latex are preferred ma- terials. Conveniently, there is no need to provide sterile gloves and preferably, the glove is intended for single use.
In a possible embodiment of the invention, the glove is packed and each pack contains two hygienically packed test gloves, wherein the test paper has a range of pH detection from 3.8 to 4.5.
The glove according to the present invention can be equipped also with other devices suitable for performing other useful tests for determining the presence of a vaginal affection by using the same sample. For ex- ample, the glove can be equipped, either on the same glove or with a separate device, with a test for volatile amines, such as the one pro- vided by FemExam®. In alternative or in addition, other test devices can be provided, for example for determining the amount of lactic acid and/or to test the activity of enzymes (sialidase, prolidase, ect..) of in- terest as markers of a pathological state, and/or other biological indica- tors (e.g. cytokines, calprotectin) or markers of infection (viral, bacte- rial, fungine). Said tests are well-known to those skilled in the art and are normally available in clinical practice. As exemplary test, the one using tetrazolium salts as a redox active substance, is mentioned.
According to the present invention, the glove is suitable for the detec- tion of vaginal affections. In a preferred embodiment of the invention, the detected vaginal affection is a vaginal infection, such as for exam- ple bacterial vaginosis, aerobic vaginitis, fungal infection or viral infec- tion, or is vaginitis.
Another need exists for detecting a vaginal affection, said method comprising the steps of: (a) securing a vaginal sample with the collecting means of the glove above described, (b) contacting said collecting means with the pH detecting means,
AMENDED SHEET
(c) reading the exposed indicator signal substance and determin- ing the predicted presence of a vaginal affection.
According to this method, collecting means, for example placed on in- dex finger, must be inserted in the vagina and applied promptly on de- tecting means, placed on the thumb finger. The pH indicator changes its colour depending on the vaginal pH and the result should be imme- diately compared to a test paper, which can be contained in each pack.
The absorbent gauze on the index finger is useful to absorb the excess mucus to be applied on the test strip. This way, no chemicals can go into the vagina and there are no risks of allergies or inflammation.
A normal pH does not mean total protection, but the method according to the present invention is particularly advisable if the woman has ex- perienced vaginal infections and allows her to check if the acidity of her vagina is normal in between check-ups with her doctor.
The device according to the present invention is useful, convenient and more efficient with respect to other available products, such as the above mentioned CarePlan® VpH and FemExam®, in particular be- cause the pH test paper come into close contact with the vagina, hence no chemicals are introduced into the vagina and there is no risk of al- lergies or inflammation. The result is immediately read thanks to the colour scale into the pack.
Once an abnormality or change in condition is observed and it is ap- parent therapy is advisable, treatment is instituted.
A further need exists to treat a vaginal affection comprising the steps of: a) determining the presence of a vaginal affection by means of the glove above disclosed, and, if the affection is present, b) topically applying to the affected area a gynecological compo- sition.
AMENDED SHEET
Although any gynecological composition known in the art and suitable for the treatment of a vaginal affection can be used in connection with the glove of the present invention, a preferred embodiment of the same provides that active ingredients to combat the affection may be se- lected from a wide range of lactic acid bacteria and/or Bifidobacteria such as Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacil- : lus casei, Lactobacillus catenaforme, Lactobacillus cellobiosus, Lacto- : bacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii,
Lactobacillus jensenii, Lactobacillus leichmannii, Lactobacillus minu- tus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rogosae, Lactobacillus salivarius, Lactobacillus brevis, Lactobacillus gasseri, Lactobacillus fermentum, Bifidobacterium adolescentis, Bifi- dobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifido- bacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum,
Bifidobacterium plantarum, Bifidobacterium pseudo-catenulatum, Bi- fidobacterium pseudolongum, Streptococcus lactis, Streptococcus raffi- nolactis, Acidaminococcus fermenta, Cytophaga fermentans, Rho- doferax fermentans, Cellulomonas fermentans, Zymomonas mobilis, and Streptococcus thermophilus.
Preferred, according to one embodiment of the invention, are those chosen from Lactobacillus brevis and Lactobacillus salivarius subsp. salicinius species optionally used in combination with one or more spe- cies of lactobacilli selected from Lactobacillus salivarius subsp. salivar- ius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus, Lactobacillus gasseri and Lactobacillus plantarum Mostly preferred is the combination consisting essentially of Lactobacillus brevis, Lactobacillus salivarius subsp. salicinius and Lactobacillus plantarum
Another preferred combination is the one consisting essentially of Lac- tobacillus brevis, Lactobacillus casei, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species
Preferably, the association of bacteria used in the pharmaceutical composition comprises or consists essentially of Lactobacillus brevis,
Lactobacillus salivarius subs. salicinius and Lactobacillus gasserti.
Particular examples of lactobacilli to be used are Lactobacillus brevis
Lactobacillus salivarius subsp. salicinius and Lactobacillus gasseri. .
Preferably, in the association of bacteria employed in accordance with the present invention the bacteria concentration is 107 to 1013 CFU/g, more preferably 108 to 1012 CFU/g, most preferably more than 10° to 1012 CFU/g. Preferably, in the association of bacteria each species is present at a concentration of 108 to 1012 CFU/g. The bacterial cultures preferably are in a lyophilized form.
The lactobacilli-containing compositions used in the present invention may also be used to treat every form of vaginitis, in particular, but not limited to, allergic vaginitis, aerobic vaginitis or other fungal vaginitis.
In a preferred embodiment of the present invention, the package com- prising the glove as above disclosed and the gynecological composition is used to prevent recurrence of bacterial vaginitis or vaginosis in women who were already affected by said disease and were treated with conventional therapy. In this embodiment, the subject will check regularly vaginal pH and, in case a bacterial affection is detected, ac- cording to the instructions provided in the package or according the subject's own experience, an adequate treatment will be instituted.
Any conventional treatment can be used. It is well known to use com- bined pharmacological treatment with antibacterial and antifungal drugs. Sterilization of vaginal environment or any other alteration of natural vaginal flora may be a side effect of this kind of treatment. In particular lactic acid bacteria naturally present in the vagina can suc- cumb to the presence of antibacterial drugs. Moreover, if the lactoba- cilli are replaced by bacteria other than the anaerobes which are typi- cal for BV, a distinct type of vaginitis may be seen. This condition is known as non-specific vaginitis, vaginitis of unknown origin, des- quamative vaginitis, or, recently, aerobic vaginitis (AV). In cases of
AV, aerobes such as Escherichia coli and Group B streptococci (GBS) are often isolated, and severe vaginal leukocytosis is accompanied by a foul smell and sticky discharge.
Adequate treatment methods are available for cases of classical an- aerobic bacterial vaginosis, for both oral and intravaginal administra- : tion. Initial cure rates of 85 to 95 percent are achieved, but the long- term cure rate is low, with up to 80% recurrences within one year. For vaginitis with disrupted vaginal flora (AV), there is no uniform, effi- cient treatment method available, and the disease is usually enduring for many months to years. Oral penicillins and macrolides cause short- term relief, only to recur after antibiotic treatment is discontinued.
Both types of vaginitis involve a severe disruption of the Lactobacillus flora. Therefore, the re-introduction of vaginal Lactobacillus acidophi- lus may be a reasonable alternative to prevent recurrence of these conditions. Lactobacilli are believed to be the main factor in vaginal resistance against infection by other bacteria, commensals and patho- gens alike. It has been proven that the loss of the Lactobacillus flora is linked to the symptoms of vaginitis, to an increased transmission risk of sexually transmitted diseases, especially HIV, and to pregnancy complications such as pre-term birth. Lactobacillary grades can be used as a pre-screening tool during pregnancy, in order to enable fur- ther investigation of cases with a high probability of infection and pre- term delivery.
Preliminary evidence suggests that a disrupted vaginal microflora can be restored to its physiological equilibrium by the application of vagi- nal tablets containing probiotics. However, it is far from clear which type of probiotic product is to be used, and the ideal way of applying the products in order to prevent recurrences are also largely unknown.
According to the present invention, once a vaginal affection is detected, adequate treatment is instituted. In a preferred embodiment, the treatment comprises the combined administration of an antibacterial agent and an antifungal agent, for example metronidazole and fucona- zole, respectively. A suitable treatment is for example 2 g of metroni- dazole orally and 200 mg of fluconazole orally. Other kind of admini- strations can be used, for example topical application, such as creams, ointments, pessaries, tablets, ovulae. After treatment, as determined according to medical advice or subject's own experience, a suitable re- colonization treatment is instituted with a composition according to the present invention containing lactic acid bacteria as above dis- closed. During the treatment, vaginal pH will be self-checked on a regular basis until restoration of a normal pH, say from about 3.8 to about 4.5 by means of the glove of the present invention. An example of suitable treatment is one vaginal tablet every second day for 8 days (4 tablets in total) containing viable lactobacilli according to the pre- sent invention. Insertion should be performed after menses or, in women with amenorrhea, monthly, in the evening before retiring. If the onset of menstruation recurs during the treatment period, treat- ment should be interrupted and resumed after menstruation has ceased. The treatment can be stopped once vaginal pH is set in the physiological interval (from about 3.8 to about 4.5).
Therefore, another need exists for the treatment and re-colonization of vaginal environment, said method comprising: a) determining the presence of a vaginal affection by means of the glove above disclosed, and, if the affection is present, b) topically applying to the affected area a gynecological composition in order to treat the vaginal affection, c) checking the disappearance of the vaginal affection, and d) topically applying a gynecological composition comprising lactic acid bacteria, checking vaginal pH by means of the glove above disclosed.
The gynecological composition comprising lactic acid bacteria and/or
Bifidobacteria can be any composition disclosed in the present inven- tion. One of the preferred compositions comprises the combination of
AMENDED SHEET the following strains: Lactobacillus brevis, Lactobacillus salivarius subsp. salicinius and Lactobacillus plantarum.
According to this embodiment, the present invention also provides a package comprising: Te a) at least one glove; Co b) a gynecological composition for the treatment of a vaginal af- fection; ¢) a gynecological composition comprising lactic acid bacteria and/or Bifidobacteria; and d) instructions for using the glove a) the composition b) and the composition c).
A convenient embodiment of the present invention provides a package containing: a) a composition comprising a combination of an antibiotic agent, for example metronidazole, with an antifungal agent, for exam- ple fuconazole, in a dosage form suitable for treating a vaginal affec- tion, such as bacterial vaginosis or aerobic vaginitis; b) a gy- necological composition for topical application comprising lactic acid bacteria and/or Bifidobacteria in a dosage form suitable for re- colonizing vaginal environment;
Cc) a sufficient number of gloves according to the present in- vention to detect a vaginal affection, to check effectiveness of treat- ment instituted with the composition under item a) and to check effec- tiveness of treatment instituted with the composition under item b); and d) instructions for using the package.
This form of package is suitable for women experiencing vaginal affec- tion and wishing to adopt a self-treatment. This package can be very convenient for travelling women or for women who cannot see a doctor very often or who are experienced with relapsing vaginal affections and have sufficient experience in self-diagnosis and self-treatment.
Another therapeutic product useful for treating vaginal conditions, particularly vaginal infections, is tea tree oil, a natural product ex- tracted from Melaleuca Alternifolia leaves, an oil extracted by distilla- tion containing tupinene-4-ol. Tea tree oil may be taken orally in a solubilized aqueous solution or applied topically or in a vaginal tablet when included in the appropriate formulating agent(s).
Other products of use for the vaginal disorders are soy and its deriva- tives. Soy contains phytoestrogens, natural occurring polyphenols ' which can be of help in the treatment of postmenopausal hormonal disorders, including osteoporosis.
For practical use the compositions used in the invention, including gy- necological, cosmetic and pharmaceutical compositions, are prepared in any convenient form for topical application such as in a liquid form, in the form of creams or ointments, or in a solid form, i.e. as pessaries or vaginal tablets, packets and the like. The compositions made in the form of vaginal tablets can be of at least one layer or at least two lay- ers having differentiated release times.
In one embodiment of the invention, the compositions of the present invention can be prepared in the form of tablets made up of two or more layers. Tea tree oil and/or soy may also be included in one or both layers of the tablet. Such two layers, both containing a species of lacto- bacilli, bound with usual excipients and additives, can be arranged in such a manner that bacteria in the outer layer are released in a lapse of time of 10-25 minutes, about 15-20 minutes for example, whereas bacteria of the inner layer are released subsequently in a lapse of time of 25-50 minutes, about 30-40 minutes for example.
The compositions may also contain a buffering agent capable of main- taining an intravaginal pH stabilized in a range between 3 and 5.5 for some hours after administration. The buffering agent is a buffer sys- tem consisting of a weak acid selected from any pharmaceutically- acceptable inorganic or organic weak acid, such as boric acid, lactic acid, ascorbic acid, citric acid or acetic acid for example, in combination with the respective sodium salt or another pharmaceutically accept- able salt of the conjugated base of the weak acid used. Preferably, the pH is buffered in a range of 4.2 to 4.5 and preferably the buffer agent used is a buffer system made up of lactic acid and sodium lactate or ascorbic acid and sodium ascorbate. These and related compositions are described in De Simone et al U.S. 6,277,370 the entire content of which is incorporated by reference.
In another preferred embodiment of the invention the pharmaceutical compositions used for therapy herein are described in De Simone WO 00/78322 A2 and its counterpart U.S. application Serial No. 10/024,199 filed December 21, 2001, the entire content of which is hereby incorpo- rated by reference. This embodiment employs a combination of lactic acid bacteria including (a) a first component consisting of at least one strain of an HaOz-producing lactic acid bacteria and (b) a second com- ponent consisting of a strain of arginine-utilizing bacteria.
The lactic acid bacteria in component (b) is the Lactobacillus brevis
CD2 strain deposited under the Budapest Treaty under accession no.
DSM 11988. The ratio of the amounts of bacteria in components (a):(b) will range from 100:1 to 1:100, preferably 1:5 to 5:1 and desirably in a substantially equal ratio of 1:1. Generally a unit dosage will contain 1 x 102 to 5 x 101! bacteria of component (a) and from 1 x 102 to 5 x 1011 bacteria of component (b) with preferred amounts being 1 x 10° bacte- ria for component (a) and 3 x 10? bacteria of component (b).
A preferred combination of lactic acid bacteria contains (a) a first com- ponent consisting of at least one strain of H2Oz-producing lactic acid bacteria, and (b) a second component consisting of at least one strain of arginine-utilizing lactic acid bacteria, where component (a) is selected from strains of the species Lactobacillus crispatus, Lactobacillus sali- varius, preferably subsp. salicinius and Lactobacillus casei, and com- ponent (b) is selected from strains of the species Lactobacillus brevis,
Lactobacillus gasseri and Lactobacillus fermentum.
This particular combination of Hz0z-producing lactic acid bacteria and ar- ginine-utilizing bacteria can optionally comprise one or more of the following strains Lactobacillus salivarius subs. salivarius, Lactobacillus jensenit, Lac- tobacillus catenaforme, Lactobacillus minutus, and Lactobacillus planta- rum.
Particularly preferred compositions are when component (a) is Lactobacillus crispatus and component (b) is Lactobacillus brevis or when component (a) is
Lactobacillus salivarius and component (b) is Lactobacillus brevis.
Additionally vitamins, quaternary ammonium bases, mineral salts, tea tree oil, soy and its derivatives, antioxidant agents, antiinflammatory, antihis- tamine and NO-releasing substances (such as sildenafil) may also be pre- sent.
Another need exists for providing a procedure for identifying and treating a vaginal affection, comprising the steps of: (a) securing a sample of vaginal fluid, (b) exposing the collected fluid to an indicator signal substance, (c) reading the exposed indicator signal substance and determining the predicted presence of a vaginal affection in said sample, wherein steps (a)-(c) are made by means of the glove herein disclosed, and if an affection is present, (d) applying to the area of affection a gynecological composition.
The preferred composition comprises lactic acid bacteria and/or Bifidobacte- ria as disclosed above.
As far as the industrial applicability of the present invention is concerned, the above glove and gynecological composition can be provided in the form of a package comprising: a) at least one glove; b) a gynecological composition; c) instructions for using the glove a) and the composition b).
AMENDED SHEET
It is intended that "a glove" of item a) in the package can be one single glove or a set of gloves. The number of gloves can be suitable deter- mined for carrying out the method for detecting a vaginal affection, and, if present, instituting a treatment of the affection with the compo- sition b), and using the remaining gloves periodically in order to check the effect of the treatment, until disappearance of the affection, de- tected with a normal pH, such as above 4.5.
Instructions as per item c) are not bound to any particular form. They essentially provide guidance to the user for interpreting the results given by the indicator substance after having contacted the vagina sample secured with the collecting means provided on the glove.
A first item of instruction is an interpretative reading of pH, conven- iently by means of a colour scale.
A second item of instruction is a correlation between the pH reading and the health condition or possible presence of an affection.
For example, a pH between 3.8 and 4.5, with no signs or symptoms means a normal and healthy condition. A pH lower than 3.8, together with whitish discharge and/or symptoms, such as burning and itching means a possible Candida vaginal infection. A pH higher than 4.5, with no signs or symptoms means a vaginal microenvironment, which is potentially favourable to the development of vaginal infections. A pH higher than 4.5, together with possibly malodorous vaginal discharges means dismicrobism with reduced or missing H2Os-producing lactic acid bacteria (bacterial vaginosis). A pH higher than 4.5, together with possibly malodorous vaginal discharges and/or irritation, itching means a possible infection by Trichomonas vaginalis.
Once affection is identified, the treatment can be instituted by means of the gynecological composition, in particular the one containing lactic acid bacteria and/or Bifidobacteria, as above disclosed. In some cases,
such as suspected Candida albicans or Trichomonas vaginalis infec- tion, a medical advice is suggested.
Normally the user will see a doctor, who will decide the posology for using the composition. However, a woman who already experienced vaginal affection can self-administer the gynecological composition provided in the package, according to her experience.
A possible treatment can be, for example one vaginal application, for example a tablet, per day, for 8 consecutive days, or, alternatively, one vaginal application every second day for 16 days.
Typically, a package can contain 8 vaginal tablets, two gloves and in- structions for use.
For the purposes of industrial applicability, the presen invention also relates to the use of the glove as above disclosed and of the composi- tions comprising lactic acid bacteria and/or Bifidobacteria for the preparation of a medicament for the detection of a vaginal affection and treatment thereof, A further object of the present invention is the use of the glove as above disclosed and of the compositions comprising lactic acid bacteria and/or Bifidobacteria and another composition used in the treatment of bacterial vaginisis or aerobic vaginitis, as above described for the preparation of a medicament for the detection of a vaginal affection, treatment thereof and re-colonization of vaginal en- vironment.
While the invention has been described in connection with what is presently considered to be the most practical and preferred embodi- ment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
“Comprises/comprising” when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other fea- tures, integers, steps or components or groups thereof.
AMENDED SHEET
Claims (79)
1. A glove bearing a reporter substance indicating the presence of a vaginal affection, said glove comprising first means for detecting pH and second means for collecting a vaginal sample are provided thereon.
2. The glove according to claim 1, wherein said second means for collecting vaginal sample are placed on one finger of the glove and said first means are placed on any position of the glove which can be con- tacted by the finger bearing said second means.
3. The glove according to any one of claims 1-2, wherein said means for detecting pH are placed on thumb finger and said second means are placed on the index finger or medium finger.
4. The glove according to any one of claims 1-3, wherein said means for detecting pH are set to cover pH range from 3.8 to 4.5.
5. The glove according to claim 4, wherein said means for detecting pH is a mixture of Methylorange and Bromocresol Green in a 1:5 (w/w) ratio.
6. The glove according to any one of claims 1-3, wherein said means for detecting pH are set to detect pH values equal to or above
4.5.
7. The glove according to any one of claims 1-6, wherein a piece of information about pH reading is enclosed.
8. The glove according to claim 7, wherein said piece of information 1s a colour scale.
9. The glove according to claim 6, wherein said values equal to or above 4.5 is set as a warning. AMENDED SHEET
10. The glove according to any one of claims 1-9, wherein said means for collecting vaginal sample are made of a material suitable for collecting vaginal fluid and/or mucus.
11. The glove according to claim 10, wherein said means material is an absorbent, non-woven, mono layer gauze.
12. The glove according to any one of claims 1-11, which is made of vinyl or latex.
13. The glove according to any one of claims 1-12, further compris- ing a separate device for the determination of a further test useful for determining the presence of a vaginal affection.
14. The glove according to claim 13, wherein said further test is se- lected from the group consisting of a test for volatile amines, test for determining the amount of lactic acid, test for determining the activity of enzymes of interest as markers of a pathological state and/or other biological indicators and test for determining the presence of markers of infection.
15. The glove according to any one of the preceding claims 1-14, which is useful for determining the presence of a vaginal affection se- lected from the group consisting of vaginal infection and vaginitis.
16. The glove according to claim 15, wherein said vaginal infection is selected from the group consisting of bacterial vaginosis, aerobic vaginitis, fungal infection and viral infection.
17. A package comprising: a) at least one glove of any one of claims 1-16; b) a gynecological composition; and optionally ¢) instructions for using the glove a) and the composition b).
18. The package according to claim 17, wherein said composition (b) comprises lactic acid bacteria and/or Bifidobacteria selected from the group consisting of Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cellobio- sus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus del- brueckii, Lactobacillus jensenit, Lactobacillus leichmannii, Lactobacil- lus minutus, Lactobacillus paracasei, Lactobacillus plantarum, Lacto- bacillus rogosae, Lactobacillus salivarius, Lactobacillus brevis, Lacto- bacillus gasseri, Lactobacillus fermentum, Bifidobacterium adolescen- tis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacte- rium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium plantarum, Bifidobacterium pseudo- catenulatum, Bifidobacterium pseudolongum, Streptococcus lactis, Streptococcus raffinolactis, Acidaminococcus fermenta, Cytophaga fer- mentans, Rhodoferax fermentans, Cellulomonas fermentans, Zymomo- nas mobilis, and Streptococcus thermophilus.
19. The package according to claim 18, wherein the lactic acid bac- teria are selected from the group consisting of Lactobacillus brevis and Lactobacillus salivarius subsp. salicinius species optionally in combi- nation with one or more species of lactobacilli selected from the group consisting of Lactobacillus salivarius subsp. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus, Lactobacil- lus gasseri and Lactobacillus plantarum.
20. The package according to claim 19, wherein the lactic acid bac- teria are a combination consisting of Lactobacillus brevis, Lactobacil- lus salivarius subsp. salicinius and Lactobacillus plantarum.
21. The package according to claim 18, wherein the lactic acid bac- teria are a combination of Lactobacillus brevis and Lactobacillus sali- varius subs. salicinius species. :
22. The package according to claim 18, wherein said lactic acid bac- teria is a combination of (a) a first component consisting of at least one strain of HzOz-producing lactic acid bacteria, and (b) a second compo- nent consisting of at least one strain of arginine-utilizing lactic acid bacteria
23. The package according to claim 22, wherein said lactic acid bac- teria is (a) selected from the group consisting of Lactobacillus cris- patus, Lactobacillus salivarius and Lactobacillus casei, and component (b) is selected from strains of the species Lactobacillus brevis, Lactoba- cillus gasseri and Lactobacillus fermentum.
24. The package according to claim 22, wherein the lactic acid bac- teria are a combination of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species.
25. The package according to any one of claims 18-24, wherein the lactic acid bacterium is Lactobacillus brevis CD2 DSM 11988.
26. The package according to any one of claims 22-25, wherein said composition further comprises one or more species of lactobacilli se- lected from the group consisting of Lactobacillus salivarius subs. sali- varius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus, and Lactobacillus plantarum.
27. The package according to claim 18, wherein said lactobacilli consist of the Lactobacillus brevis, Lactobacillus casei, Lactobacillus salivarius subs. salicinius and Lactobacillus gasseri species.
28. The package according to any one of claims 18-27, wherein said lactobacilli are present at a concentration of 107 to 1013 CFU/g.
29. The package according to any one of claims 18-28, wherein the } composition further comprises at least a substance selected from the group consisting of vitamins, quaternary ammonium bases, mineral salts, tea tree oil, soy and its derivatives, antioxidant agents, antiin- flammatory agents, antihistamine agents and NO-releasing substance.
30. The package according to claim 18, wherein the composition (b) comprises at least a substance selected from the group consisting of tea tree oil and/or soy and its derivatives. : :
31. The package according to claim 30, wherein the composition fur- ther comprises at least a substance selected from the group consisting of vitamins, quaternary ammonium bases, mineral salts and antioxi- dant agents.
32. The package according to any one of claims 18-31, wherein said composition is in a liquid form or a cream, ointment, pessary, vaginal tablet or packet.
33. The package according to claim 32, wherein said vaginal tablet comprises at least one layer of lactobacilli, in bound form, to control the release velocity of bacteria.
34. The package of claim 33, wherein said tablet comprises at least two layers, the outermost layer and the innermost layer containing said species of lactobacilli, in bound form, so that the release velocity of bacteria of the outermost layer is greater than the release velocity of bacteria of the innermost layer.
35. The package of claim 34, wherein in said tablet, bacteria in the outermost layer are released in a lapse of time of about 10-25 minutes, whereas bacteria of the inner layer are released subsequently in a lapse of time of about 25-50 minutes.
36. The package according to any one of claims 17-35, further com- prising (d) a composition for the treatment of bacterial vaginosis or aerobic vaginitis.
37. The package according to claim 36, wherein said composition (d) comprises a combination of an antibacterial agent and an antifungal agent.
38. The package according to claim 37, wherein said antibacterial agent is metronidazole and said antifungal agent is fuconazole.
39. The package according to any of claims 36-38, further compris- ing instructions for the use of the glove (a), composition (b) and compo- sition (d).
40. A package comprising the glove of any one of claims 1-16 and instructions for its use.
41. The use of the glove of any one of claims 1-16 and of the compo- sition as disclosed in any one of claims 17-35 for the preparation of a medicament for the detection of a vaginal affection and treatment thereof.
42. The use of the glove of any one of claims 1-16 and of the compo- sition as disclosed in any one of claims 17-39 for the preparation of a medicament for the detection of a vaginal affection, treatment thereof and re-colonization of vaginal environment.
43. Use of the glove according to any one of claims 1 to 16 for de- termining the presence of a vaginal affection, comprising the steps of: (a) securing a vaginal sample with the collecting means of the glove, (b) contacting said collecting means with the pH detecting means, (c) reading the exposed indicator signal substance and determin- ing the predicted presence of said vaginal affection. AMENDED SHEET
44. The use according to claim 43, wherein said affection is selected from the group consisting of vaginal infections, vaginitis and dyspare- unia.
45. The use according to claim 44, wherein said infection is selected from the group consisting of bacterial vaginosis, aerobic vaginitis, fun- gal infection and viral infection.
46. Use of the glove of claim 1 for treating vaginal affections com- prising the steps of: (a) determining the presence of a vaginal affection by means of the glove, and, if the affection is present, (b) topically applying to the affected area a gynecological compo- sition.
47. The use according to claim 46, wherein said affection is selected from the group consisting of vaginal infections, vaginitis and dyspare- unia.
48. The use according to claim 47, wherein said infection is selected from the group consisting of bacterial vaginosis, aerobic vaginitis, fun- gal infection and viral infection.
49. Use of the glove according to any one of claims 1 to 16 for identi- fying and treating a vaginal affection, comprising the steps of: (a) securing a sample of vaginal fluid, (b) exposing the collected fluid to an indicator signal substance, (c) reading the exposed indicator signal substance and determin- ing the predicted presence of a vaginal affection in said sample, wherein steps (a)-(c) are made by means of the glove, and if an affec- tion 1s present, (d) applying to the area of affection a gynecological composition. AMENDED SHEET
50. The use according to claim 49, wherein said affection is selected from the group consisting of vaginal infections, vaginitis and dyspare- unia.
51. The use according to claim 50, wherein said infection is selected from the group consisting of bacterial vaginosis, aerobic vaginitis, fun- gal infection and viral infection.
52. The use of claim 49, wherein the composition applied in step (d) comprises lactic acid bacteria and/or Bifidobacteria selected from the group consisting of Lactobacillus acidophilus, Lactobacillus buchnert, Lactobacillus casei, Lactobacillus catenaforme, Lactobacillus cello- biosus, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus delbrueckii, Lactobacillus jensenii, Lactobacillus leichmannii, Lactoba- cillus minutus, Lactobacillus paracaset, Lactobacillus plantarum, Lac- tobacillus rogosae, Lactobacillus salivarius, Lactobacillus brevis, Lac- tobacillus gasseri, Lactobacillus fermentum, Bifidobacterium adoles- centis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifido- bacterium breve, Bifidobacterium catenulatum, Bifidobacterium den- tium, Bifidobacterium eriksonii, Bifidobacterium infantis, Bifidobacte- rium longum, Bifidobacterium plantarum, Bifidobacterium pseudo- catenulatum, Bifidobacterium pseudolongum, Streptococcus lactis, Streptococcus raffinolactis, Acidaminococcus fermenta, Cytophaga fer- mentans, Rhodoferax fermentans, Cellulomonas fermentans, Zymomo- nas mobilis, and Streptococcus thermophilus.
53. The use of claim 52, wherein the lactic acid bacteria are selected from the group consisting of Lactobacillus brevis and Lactobacillus salivarius subsp. salicinius species optionally in combination with one or more species of lactobacilli selected from the group consisting of Lactobacillus salivarius subsp. salivarius, Lactobacillus jensenii, Lac- tobacillus catenaforme, Lactobacillus minutus, Lactobacillus gasseri and Lactobacillus plantarum. AMENDED SHEET
54. The use of claim 52, wherein the lactic acid bacteria are a com- bination consisting of Lactobacillus brevis, Lactobacillus salivarius subsp. salicinius and Lactobacillus plantarum.
55. The use of claim 52, wherein the lactic acid bacteria are a com- bination of Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species.
56. The use of claim 53, wherein said lactic acid bacteria is a combi- nation of (a) a first component consisting of at least one strain of H203- producing lactic acid bacteria, and (b) a second component consisting of at least one strain of arginine-utilizing lactic acid bacteria
57. The use of claim 52, wherein said lactic acid bacteria is (a) Lac- tobacillus crispatus or Lactobacillus salivarius and (b) is Lactobacillus breurs.
58. The use of claim 52, wherein the lactic acid bacteria is Lactoba- cillus brevis CD2 DSM 11988.
59. The use of claim 52, wherein the composition further comprises at least a substance selected from the group consisting of vitamins, quaternary ammonium bases, mineral salts, tea tree oil, soy and its derivatives, antioxidant agents, antiinflammatory agents, antihista- mine agents and NO-releasing substance.
60. The use of claim 52, wherein the lactic acid bacteria are a com- bination of the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species.
61. The use of claim 56, wherein said composition further comprises one or more species of lactobacilli selected from the group consisting of Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lacto- bacillus catenaforme, Lactobacillus minutus, Lactobacillus gasseri, Lactobacillus caset and Lactobacillus plantarum. AMENDED SHEET
62. The use of claim 52, wherein said lactobacilli consist of the Lac- tobacillus brevis, Lactobacillus casei, Lactobacillus salivarius subs. salicinius and Lactobacillus gassert species.
63. The use of claims 52, wherein said lactobacilli are present at a concentration of 107 to 1013 CFU/g.
64. The use of claim 52, wherein said composition is in the form of a liquid composition or a cream, ointment, pessary, vaginal tablet or packet.
65. The use of claim 60, wherein said vaginal tablet comprises at least one layer of lactobacilli, in bound form, to control the release velocity of bacteria.
66. The use of claim 61, wherein said tablet comprises at least two layers, the outermost layer and the innermost layer containing said species of lactobacilli, in bound form, so that the release velocity of bacteria of the outermost layer is greater than the release velocity of bacteria of the innermost layer.
67. The use of claim 62, wherein in said tablet, bacteria in the out- ermost layer are released in a lapse of time of about 10-25 minutes, whereas bacteria of the inner layer are released subsequently in a lapse of time of about 25-50 minutes.
68. A gynecological composition comprising lactic acid bacteria and/or Bifidobacteria for use in the treatment of vaginitis.
69. A gynecological composition comprising lactic acid bacteria and/or Bifidobacteria for use in the prevention or treatment of dyspareunia. AMENDED SHEET
70. The glove of claim 1 for use in the treatment of vaginal affec- tions and re-colonizing vaginal environment comprising the steps of: (a) determining the presence of a vaginal affection by means of the glove, and, if the affection is present, (b) treating the affection; and once the affection is treated; (c) topically applying to the affected area a gynecological compo- sition comprising lactic acid bacteria and/or Bifidobacteria; and (d) during step (c) checking vaginal pH by means of the glove, until normal vaginal pH.
71. A composition comprising tea oil and/or soy and its derivatives for use in the treatment of vaginal affections comprising the steps of: (a) determining the presence of a vaginal affection and, if pre- sent (b) topically applying said composition to the affected area.
72. The glove as claimed in any one of claims 1 to 16 and 70, sub- stantially as hereinbefore described or exemplified.
73. The glove including any new and inventive integer or combina- tion of integers, substantially as herein described.
74. The package as claimed in any one of claims 17 to 40, substan- tially as hereinbefore described or exemplified.
75. The package including any new and inventive integer or combi- nation of integers, substantially as herein described.
76. The use of the glove as claimed in any one of claims 41 to 67, substantially as hereinbefore described or exemplified.
77. The use of the glove including any new and inventive integer or combination of integers, substantially as herein described. AMENDED SHEET
78. The gynaecological composition as claimed in claim 68 or 71, substantially as hereinbefore described or exemplified.
79. The gynaecological composition including any new and inventive integer or combination of integers, substantially as herein described. AMENDED SHEET
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200704464A ZA200704464B (en) | 2007-05-30 | 2007-05-30 | Device and method for identifying and treating vaginal affections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA200704464A ZA200704464B (en) | 2007-05-30 | 2007-05-30 | Device and method for identifying and treating vaginal affections |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200704464B true ZA200704464B (en) | 2008-07-30 |
Family
ID=40677293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200704464A ZA200704464B (en) | 2007-05-30 | 2007-05-30 | Device and method for identifying and treating vaginal affections |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200704464B (en) |
-
2007
- 2007-05-30 ZA ZA200704464A patent/ZA200704464B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI425210B (en) | Device and method for identifying and treating vaginal affections | |
Pendharkar et al. | Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection | |
De Seta et al. | Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study | |
US20060057132A1 (en) | Identifying and treating vaginal infections | |
McLEAN et al. | Characterisation and selection of a Lactobacillus species to re-colonise the vagina of women with recurrent bacterial vaginosis | |
Russo et al. | Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota | |
Daniel Johannes Rönnqvist et al. | Lactobacilli in the female genital tract in relation to other genital microbes and vaginal pH | |
Spiegel et al. | Curved anaerobic bacteria in bacterial (nonspecific) vaginosis and their response to antimicrobial therapy | |
Razzak et al. | Relationship between lactobacilli and opportunistic bacterial pathogens associated with vaginitis | |
Goulet et al. | Isolation of Mycoplasma pneumoniae from the human urogenital tract | |
Decena et al. | Metronidazole with Lactacyd vaginal gel in bacterial vaginosis | |
Kwok et al. | Adherence of Lactobacillus crispatus to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection | |
Roth et al. | The urobiome in men and women: A clinical review | |
Giraldo et al. | The effect of “breathable” panty liners on the female lower genital tract | |
Mohammed et al. | Live Bacteria Supplementation as Probiotic for Managing Fishy, Odorous Vaginal Discharge Disease of Bacterial Vaginosis: An Alternative Treatment Option? | |
Kelly et al. | Inhibition of vaginal lactobacilli by a bacteriocin-like inhibitor produced by Enterococcus faecium 62-6: potential significance for bacterial vaginosis | |
Schwiertz et al. | Effectiveness and tolerability of a synbiotic vaginal suppository for the treatment of bacterial vaginosis | |
ZA200704464B (en) | Device and method for identifying and treating vaginal affections | |
NZ555546A (en) | Device and method for identifying and treating vaginal affections | |
JP2011156392A (en) | Device for and method for identifying and treating vaginal affection | |
RAJAN et al. | Prevalence and Antibiotic Susceptibility Patterns of Mycoplasma hominis and Ureaplasma urealyticum in Females with Genital Infections from Central Kerala, India. | |
Enitan et al. | Prevalence of Bacterial Vaginosis and Associated Risk Factors Among Non-pregnant Women in Ilara Community of Ogun State, Nigeria | |
Eifediyi et al. | Clinical epidemiology and diagnosis of Bacterial vaginosis among pregnant women attending clinics in Irrua Specialist Teaching Hospital, Edo State, Nigeria. Special Pathogens Review Journal,(SPRJ); 2015, Vol 1 No 1, Pg: 000118-00029 ABSTRACT Background: Bacterial vaginosis (BV) may be common in women of reproductive age group but little is known about the pattern of vaginal flora associated with BV in Nigeria sub-rural population. Objectives: This study was designed to determine the prevalence, etiology, and standard diagnosis of bacterial vaginosis in Irrua Specialist Teaching Hospital Edo State, Nigeria | |
Sumangala | Comparative Study of Aerobic Bacterial Isolates in Superficial Swab and Deep Tissue Biopsy Cultures Among Type 2 Diabetes Mellitus Patients with Foot Ulcers | |
Massiha et al. | A study on antimicrobial resistance of Helicobacter pylori isolates recovered from dyspeptic patients by epsilometer test |